Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 2008

View Archived Issues

Snapshots on the GlaxoSmithKline's antimalarial vaccines under clinical development in children

Recent clinical study results for anticoagulant DU-176b

Recent patents impart novel anticancer agents

TorreyPines describes new agents for Alzheimer's disease in recent patent

Dr. Reddy's patents novel antibacterial agents

Novocell and Pfizer enter collaboration for pancreatic progenitor cells derived from hES cells

Development of TPI-1020 in COPD discontinued

Oncolytics completes patient enrollment in REO-010 and REO-008 clinical trials of Reolysin

Pfizer and Celldex amend ACT III phase Ib/III clinical trial of CDX-110 in GBM

Genmab and GSK amend worldwide agreement to codevelop and commercialize Arzerra

AMAG receives complete response letter from FDA for ferumoxytol in kidney disease

TopoTarget reports further results from three phase II studies of NAD+ inhibitor APO-866

Phase II study of catumaxomab in gastric cancer meets primary endpoint

Evolva files CTA in Germany for phase I study of EV-077-3201-2TBS

BioCryst reports data for forodesine HCl in chronic lymphocytic leukemia

NPS commences phase III REPLACE study for NPSP-558 in hypoparathyroidism

Sanofi-aventis presents results from DIONYSOS trial in atrial fibrillation

AstraZeneca receives complete response letter for Seroquel XR for MDD

Northwest reports positive results from phase I/II clinical of DCVax-L in ovarian cancer

European Commission grants marketing authorization to Celgene's Vidaza in MDS and AML

Neuren discontinues Glypromate development following pivotal trial

Intercell initiates phase II trial for Pseudomonas aeruginosa vaccine

King commences phase II T-62 trial in neuropathic pain

Phase I study shows HA-22 highly active in hairy cell leukemia

Celsentri tablets approved in Japan for HIV

Addition of BSI-201 to gemcitabine/carboplatin feasible in triple negative breast cancer

Phase I and II data on trastuzumab-DM1 in HER2+ breast cancer reported

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...